[1] Sjøbakk TE, Vettukattil R, Gulati M, et al. Metabolic profiles of brain metastases. Int J Mol Sci. 2013. 14(1): 2104-18.
[2] Oschmann P, Kaps M, Völker J, Dorndorf W. Meningeal carcinomatosis: CSF cytology, immunocytochemistry and biochemical tumor markers. Acta Neurol Scand. 1994. 89(5): 395-9.
[3] Jorda M, Ganjei-Azar P, Nadji M. Cytologic characteristics of meningeal carcinomatosis: increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol. 1998. 55(2): 181-4.
[4] Li N, Yang BY, Li JL, et al. [Clinical features and prognostic factors in patients with leptomeningeal metastases]. Zhonghua Zhong Liu Za Zhi. 2013. 35(11): 867-70.
[5] Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990. 9(3): 225-9.
[6] Corbin ZA, Nagpal S. Leptomeningeal Metastases. JAMA Oncol. 2016. 2(6): 839.
[7] Gauthier H, Guilhaume MN, Bidard FC, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 2010. 21(11): 2183-2187.
[8] Almajed MM, Esfahani K, Pelmus M, Panasci L. Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy. BMJ Case Rep. 2016. 2016.
[9] Niwińska A, Pogoda K, Michalski W, Kunkiel M, Jagiełło-Gruszfeld A. Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM). J Neurooncol. 2018. 138(1): 191-198.
[10] Griguolo G, Pouderoux S, Dieci MV, et al. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. Oncologist. 2018. 23(11): 1289-1299.
[11] Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979. 29(10): 1369-75.
[12] Pavlidis N. The diagnostic and therapeutic management of leptomeningeal carcinomatosis. Ann Oncol. 2004. 15 Suppl 4: iv285-91.
[13] Stojmenović GM, Pavlović AM, Gazibara MS, Grujicić D, Radojicić A, Sternić NC. Leptomeningeal carcinomatosis can be presenting manifestation of breast carcinoma. Vojnosanit Pregl. 2016. 73(3): 293-5.
[14] Yust-Katz S, Garciarena P, Liu D, et al. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 2013. 114(2): 229-35.
[15] Sacco K, Muhammad A, Saleem W, et al. Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer. Oncol Lett. 2016. 12(2): 779-782.
[16] Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med. 1991. 115(5): 507-10.
[17] Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol. 2013. 30(1): 408.
[18] Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996. 53(7): 626-32.
[19] Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol. 2010. 22(6): 627-35.
[20] Lee S, Ahn HK, Park YH, et al. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011. 129(3): 809-17.
[21] Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999. 5(11): 3394-402.
[22] Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol. 2009. 36(4 Suppl 2): S35-45.
[23] Brem SS, Bierman PJ, Black P, et al. Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005. 3(5): 644-90.
[24] Chamberlain MC, Junck L. Defining patients at risk for neoplastic meningitis: what parameters can be used to determine who should be treated. Expert Rev Neurother. 2004. 4(4 Suppl): S3-10.
[25] de Azevedo CR, Cruz MR, Chinen LT, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol. 2011. 104(2): 565-72.
[26] Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012. 7(2): 382-5.
[27] Altundag K, Bondy ML, Mirza NQ, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007. 110(12): 2640-7.
[28] Scott BJ, van Vugt VA, Rush T, et al. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014. 119(2): 361-8.
[29] Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol. 2010. 136(11): 1729-35.
[30] Du C, Hong R, Shi Y, Yu X, Wang J. Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients. J Neurooncol. 2013. 115(2): 285-91.
[31] Kwon J, Chie EK, Kim K, et al. Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. J Korean Med Sci. 2014. 29(8): 1094-101.
[32] Brower JV, Saha S, Rosenberg SA, Hullett CR, Ian Robins H. Management of leptomeningeal metastases: Prognostic factors and associated outcomes. J Clin Neurosci. 2016. 27: 130-7.
[33] Au HJ, Eiermann W, Robert NJ, et al. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013. 18(7): 812-8.
[34] Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014. 32(33): 3744-52.
[35] Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008. 19(6): 1090-6.
[36] Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011. 50(3): 344-52.